Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma — − Expanding Program to Include Colorectal Cancer, Castration-resistant Prostate Cancer, and Myelodysplastic Syndrome — NEWTON, Mass., Dec.
View HTML
Toggle Summary Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex — − SVd Arm Continues to Show High Response Rates, Including 83% ORR and >13-month PFS in BOSTON Patient Population; 63% ORR in the Overall Study
View HTML
Toggle Summary Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November 16,
View HTML
Toggle Summary Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November
View HTML
Toggle Summary Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia — − Michael Falvey Named Chief Financial Officer— − Fourteen Abstracts Selected for ASH 2017,
View HTML
Toggle Summary Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting
    Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting  
View HTML
Toggle Summary Karyopharm to Report Third Quarter 2017 Financial Results on November 2, 2017
Conference Call Scheduled for Thursday, November 2, 2017 at 8:30 a.m. ET
View HTML
Toggle Summary Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries — − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to Receive up to ¥19.15
View HTML
Toggle Summary Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death — — Phase 3 Portion of Study Commenced; Expanded to Include North America and Europe and Expected to Enroll Up To 222
View HTML
Toggle Summary Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies — —  Jatin Shah, MD, Formerly Associate Professor and Director of the Myeloma
View HTML